Latest On PLx Pharma Inc (PLXP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-12 20:54 EST | News | PLx Pharma intends to file for bankruptcy, inks stalking horse deal; stock +9% after hours | N/A |  |
| 2023-04-11 17:35 EST | News | PLx Pharma to be delisted from the Nasdaq on April 13 | N/A | |
| 2022-11-11 15:17 EST | News | PLx Pharma GAAP EPS of -$0.30, revenue of $0.39M | N/A | |
| 2022-11-11 15:17 EST | News | PLx Pharma Non-GAAP EPS of -$0.37, revenue of $0.39M | N/A | |
| 2022-11-11 15:16 EST | News | PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript | N/A | |
About PLx Pharma Inc (PLXP):
PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery sy read more...stem, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.
General
- Name PLx Pharma Inc
- Symbol PLXP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 8
- Last Split Factor1:8
- Last Split Date2017-04-20
- Fiscal Year EndDecember
- IPO Date2014-03-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://plxpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 1333.99
- Enterprise Value Revenue 3293.12
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.03
- Next Year EPS Estimate -$0.76
- Operating Margin -44230%
- Return on Assets -37%
- Return on Equity -192%
- Revenue 30430
- Earnings Per Share -$3.87
- Revenue Per Share $0
- Gross Profit 30430
- Quarterly Earnings Growth -100%
Highlights
- Market Capitalization 222.44 million
- EBITDA -11888050
- PEG Ratio -0.11
- Analyst Target Price $12
- Book Value Per Share -$1.50
Share Statistics
- Shares Outstanding 21.79 million
- Shares Float 18.48 million
- % Held by Insiders 535%
- % Held by Institutions 54.55%
- Shares Short 668214
- Shares Short Prior Month 620455
- Short Ratio 4.37
- Short % of Float 5%
- Short % of Shares Outstanding 5%
Technicals
- Beta 5.16
- 52 Week High $10.38
- 52 Week Low $1.8
- 50 Day Moving Average 7.52
- 200 Day Moving Average 5.23
Dividends
- Dividend Date 2017-04-20
- ExDividend Date N/A
- Dividend Yield 0%
PLx Pharma Inc (PLXP) Dividend Calendar:
PLXP's last dividend payment was made to shareholders on April 20, 2017.
PLx Pharma Inc (PLXP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
PLx Pharma Inc (PLXP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
PLx Pharma Inc (PLXP) Chart:
PLx Pharma Inc (PLXP) News:
Below you will find a list of latest news for PLx Pharma Inc (PLXP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
PLx Pharma Inc (PLXP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PLXP Trades:
PLx Pharma Inc (PLXP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-30 | 8-K (Current report) | |
| 2020-09-25 | DEF 14A (Other definitive proxy statements) | |
| 2020-09-22 | 8-K (Current report) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-14 | 8-K (Current report) | |
| 2020-08-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-08 | EFFECT (Notice of Effectiveness) | |
| 2020-07-06 | CORRESP (Correspondence) | |
| 2020-07-02 | UPLOAD (SEC-generated letter) | |
| 2020-06-30 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-06-30 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-05-29 | D (Notice of Exempt Offering of Securities) | |
| 2020-05-26 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-05-20 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-05-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-18 | 8-K (Current report) | |
| 2020-05-15 | 8-K (Current report) | |
| 2020-05-15 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-05-04 | 8-K (Current report) | |
PLx Pharma Inc (PLXP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PLx Pharma Inc (PLXP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 535%
Institutional Ownership: 5455%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-02 | Rita M O'Connor | Chief Financial Officer | Buy | 2,120.00 | 3.83 | 8,126.60 | 12,970.00 | |
| 2020-09-01 | Rita M O'Connor | Chief Financial Officer | Buy | 4,500.00 | 3.74 | 16,837.20 | 10,850.00 | |
| 2020-08-21 | Rita M O'Connor | Chief Financial Officer | Buy | 4,050.00 | 3.97 | 16,090.65 | 6,350.00 | |
| 2020-08-20 | Rita M O'Connor | Chief Financial Officer | Buy | 2,300.00 | 3.77 | 8,665.71 | 2,300.00 | |
| 2019-05-20 | Michael J Valentino | Executive Chairman | Buy | 44,404.00 | 5.60 | 248,662.40 | 196,790.00 | |
| 2018-12-27 | Park West Asset Management LLC | 10% Share Holder | Buy | 397,495.00 | 1.00 | 397,495.00 | 1,473,218.00 | |
| 2017-08-10 | Michael J Valentino | Executive Chairman | Buy | 30,000.00 | 152,386.00 | | ||
| 2017-06-14 | Michael J Valentino | Executive Chairman | Buy | 29,091.00 | 6.88 | 200,000.63 | 122,386.00 | |
| 2017-06-14 | DAVID EMERSON JORDEN | Acting Chief Financial Officer | Buy | 32,727.00 | 6.88 | 224,998.13 | 151,913.00 | |
| 2017-06-14 | GARY L MOSSMAN | Chief Operating Officer | Buy | 7,273.00 | 6.88 | 50,001.88 | 78,255.00 | |